Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
The introduction of tyrosine kinase inhibitors in 2001 as a targeted anticancer therapy has significantly improved the quality of life and survival of patients with chronic myeloid leukemia. At the same time, with the introduction of tyrosine kinase inhibitors, the need for precise monitoring of the...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3287 |
id |
doaj-350e100ec88f4e4080d553011f29ce98 |
---|---|
record_format |
Article |
spelling |
doaj-350e100ec88f4e4080d553011f29ce982020-11-25T04:07:38ZengMDPI AGCancers2072-66942020-11-01123287328710.3390/cancers12113287Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCRAleksandar Jovanovski0Jessica Petiti1Emilia Giugliano2Enrico Marco Gottardi3Giuseppe Saglio4Daniela Cilloni5Carmen Fava6Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Turin, ItalyDivision of Internal Medicine and Hematology, San Luigi Gonzaga Hospital, Orbassano, 10043 Turin, ItalyDivision of Internal Medicine and Hematology, San Luigi Gonzaga Hospital, Orbassano, 10043 Turin, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Turin, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Turin, ItalyDepartment of Clinical and Biological Sciences, University of Turin, 10043 Turin, ItalyThe introduction of tyrosine kinase inhibitors in 2001 as a targeted anticancer therapy has significantly improved the quality of life and survival of patients with chronic myeloid leukemia. At the same time, with the introduction of tyrosine kinase inhibitors, the need for precise monitoring of the molecular response to therapy has emerged. Starting with a qualitative polymerase chain reaction, followed by the introduction of a quantitative polymerase chain reaction to determine the exact quantity of the transcript of interest-p210 BCR-ABL1, molecular monitoring in patients with chronic myeloid leukemia was internationally standardized. This enabled precise monitoring of the therapeutic response, unification of therapeutic protocols, and comparison of results between different laboratories. This review aims to summarize the steps in the diagnosis and molecular monitoring of p210 BCR-ABL1, as well as to consider the possible future application of a more sophisticated method such as digital polymerase chain reaction.https://www.mdpi.com/2072-6694/12/11/3287BCR-ABL1Chronic myeloid leukemiamolecular monitoringinternational scaleconversion factorMMR |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aleksandar Jovanovski Jessica Petiti Emilia Giugliano Enrico Marco Gottardi Giuseppe Saglio Daniela Cilloni Carmen Fava |
spellingShingle |
Aleksandar Jovanovski Jessica Petiti Emilia Giugliano Enrico Marco Gottardi Giuseppe Saglio Daniela Cilloni Carmen Fava Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR Cancers BCR-ABL1 Chronic myeloid leukemia molecular monitoring international scale conversion factor MMR |
author_facet |
Aleksandar Jovanovski Jessica Petiti Emilia Giugliano Enrico Marco Gottardi Giuseppe Saglio Daniela Cilloni Carmen Fava |
author_sort |
Aleksandar Jovanovski |
title |
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR |
title_short |
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR |
title_full |
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR |
title_fullStr |
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR |
title_full_unstemmed |
Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR |
title_sort |
standardization of bcr-abl1 p210 monitoring: from nested to digital pcr |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-11-01 |
description |
The introduction of tyrosine kinase inhibitors in 2001 as a targeted anticancer therapy has significantly improved the quality of life and survival of patients with chronic myeloid leukemia. At the same time, with the introduction of tyrosine kinase inhibitors, the need for precise monitoring of the molecular response to therapy has emerged. Starting with a qualitative polymerase chain reaction, followed by the introduction of a quantitative polymerase chain reaction to determine the exact quantity of the transcript of interest-p210 BCR-ABL1, molecular monitoring in patients with chronic myeloid leukemia was internationally standardized. This enabled precise monitoring of the therapeutic response, unification of therapeutic protocols, and comparison of results between different laboratories. This review aims to summarize the steps in the diagnosis and molecular monitoring of p210 BCR-ABL1, as well as to consider the possible future application of a more sophisticated method such as digital polymerase chain reaction. |
topic |
BCR-ABL1 Chronic myeloid leukemia molecular monitoring international scale conversion factor MMR |
url |
https://www.mdpi.com/2072-6694/12/11/3287 |
work_keys_str_mv |
AT aleksandarjovanovski standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT jessicapetiti standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT emiliagiugliano standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT enricomarcogottardi standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT giuseppesaglio standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT danielacilloni standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr AT carmenfava standardizationofbcrabl1p210monitoringfromnestedtodigitalpcr |
_version_ |
1724428067031482368 |